#XPOVIO #Antengene #Selinexor

Antengene's Commercial Growth in APAC: XPOVIO® Approved in Indonesia

Antengene Corporation Limited, a prominent global biopharmaceutical company, recently marked a pivotal moment in its expansion within the Asia-Pacific (APAC) healthcare market with the approval of XPOVIO® (selinexor) in Indonesia. On March 5, 2025, the Indonesia National Agency of Drug and Food Control (BPOM) granted approval for a new drug application (NDA), establishing XPOVIO® as the first and only XPO1 inhibitor available in the country.

This breakthrough comes as part of a broader strategy that has seen XPOVIO® successively approved in Thailand, Malaysia, and now Indonesia since mid-2024. The medication is now recognized for its efficacy in treating multiple conditions, including severe forms of multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL). The health implications of this reach beyond mere approvals; they signify a commitment to enhance medical care across this growing region.

The Significance of XPOVIO® in Cancer Treatment

XPOVIO® operates through a unique mechanism as an orally-available, selective inhibitor of the nuclear export protein XPO1. This innovative approach allows the drug to enhance intranuclear concentrations of tumor suppressor proteins while simultaneously down-regulating several oncogenic proteins. The versatile efficacy adds substantial value to treatment plans for patients battling MM and DLBCL, particularly those who have exhausted other therapies.

The approved indications include:
1. Combination therapy with bortezomib and dexamethasone for adult patients with relapsed or refractory multiple myeloma (R/R MM) after at least one prior treatment.
2. Combination with dexamethasone for R/R MM after multiple previous therapies and proven refractoriness to prior treatments.
3. Monotherapy for adults suffering from DLBCL, who are not eligible for hematopoietic cell transplantation.

Antengene's Broader Ambition in the ASEAN Region

Antengene's strategy to boost its presence in the ASEAN market aligns with the region's economic growth and demographic shifts—over 600 million people, many of whom are aging and experiencing higher incidences of chronic diseases. The demand for innovative treatments is on the rise, and Antengene aims to address this need, enhancing the quality of healthcare and enriching patients' lives.

The company’s focus on expanding XPOVIO®'s indications further demonstrates its commitment to developing additional combination regimens targeting other serious conditions like myelofibrosis and endometrial cancer. This forward-thinking ambition reflects Antengene's vision of